The first Food and Drug Administration approvals for cell and gene therapies are already more than a year out, but 2019 is likely to be a significant year for the field, particularly in areas like international interest, industry consolidation and pricing. That was the theme of a panel discussion Monday morning at Biotech Showcase in San Francisco, which coincides with the 2019 J.P. Morgan Healthcare Conference.


In wrapping up the year, AGT was proud to be featured as a State of Maryland “Success Story” for its growth in Maryland and achievements in the gene and cell therapy industry.


Now in its 37th year, the conference has ballooned from a small event with 150 attendees that was essentially the " birth of biotech," to an event attended by everyone from the biggest pharma company to the smallest biotech. JPMorgan said more than 485 companies are scheduled to present this year.


Congratulations to Bahija on making MedImmune the leading BioHealth company in Maryland and accelerating its growth. Also many thanks for the MedImmune longtime support of BHI and helping the BioHealth Capital Region become the 4th largest Life Science region in the country.

Six years after AstraZeneca’s then new CEO Pascal Soriot named Bahija Jallal president of the big MedImmune subsidiary in Gaithersburg, MD, putting her at the center of the company’s R&D turnaround plans, the longtime pharma exec is joining the great migration of industry professionals to biotech.


Many thanks to Dan for his leadership of Emergent, his service as a loyal BHI Board Member and for helping accelerate the growth of the BIO Health Capital Region

Emergent BioSolutions Inc. (EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed Robert G. Kramer, Sr., the company’s current president and COO, to succeed him as president and CEO, effective April 1, 2019. Mr. Abdun-Nabi has also indicated that he plans to step down as a member of the Emergent board of directors, and Emergent expects the board of directors to appoint Mr. Kramer to fill the board vacancy created by Mr. Abdun-Nabi’s retirement.


Here is a significant opportunity for MARYLAND to grow in SBIR success.

One of the best ways to measure the effectiveness of state programs intended to encourage the success of SBIR applications is the approval-rate of their submissions. Although this data has been historically unavailable across every federal agency, it is now accessible for the National Institutes of Health (NIH), the second largest provider of SBIR/STTR awards, according to a 2018 Digest report. The NIH distributed $446.2 million in SBIR/STTR awards in 2017, with every state except North and South Dakota receiving an award. Although California and Massachusetts had the most successful SBIR/STTR applications in 2017, accounting for roughly one-third of the total when combined, neither state ranked among the top 10 in success rate.


A biotechnology venture capital firm is ringing in the new year with its latest fund, having raised a quarter of $1 billion.

Cambridge, Massachusetts-based Atlas Venture said Wednesday that it closed its first Opportunity Fund, or AVOF I, with an oversubscribed fund raise of $250 million. The firm plans to invest the money in companies already in its portfolio.


Tuesday, January 15, 2019 8:30AM - 10:30AM

GSK 9911 Belward Campus Drive Rockville, MD 20850

The Maryland Life Sciences, a division of the Maryland Tech Council, brings together vaccine leaders to discuss current breakthroughs in the world of vaccines and immunotherapeutics. This breakfast meeting will address innovating strategies to meet current health threats, changing technology for vaccine manufacturing and provide a snapshot of where vaccine development stands today.

Join us for breakfast, networking and a discussion to hear about the experiences and insights on the current state and projected future of treatments. Local leaders will also discuss challenges and opportunities that come with vaccine and immunotherapy development used by companies in our State.


Different places have different levels of educational achievement.

The American Community Survey is an annual survey run by the Census Bureau to allow the government, corporate and academic researchers, and anyone who is curious about demographics to better understand the US population. Among many other subjects, the ACS includes questions about respondents' education levels.


The biopharma industry continues to face challenges this year, with projected returns on investment in R&D at the lowest levels since our analysis began in 2010. However, there are opportunities to reverse this trend, which will require new ways of working and a complete digital transformation to unlock R&D productivity and deliver the next generation of scientific breakthroughs.


The University of Maryland, Baltimore has granted Educational & Scientific, LLC an exclusive license with the potential to treat prostate cancer, UM Ventures announced Monday. The agreement allows Educational & Scientific to develop Galeterone, a molecule that could inhibit prostate cancer growth in patients with castration-resistant prostate cancer. The molecule has had successful Phase 1 and Phase ...


The research institute founded and headed by J. Craig Venter, Ph.D., yesterday won the dismissal of a federal lawsuit filed against it by the company he co-founded four years ago to develop and apply large-scale computing and machine learning toward making discoveries intended to revolutionize the practice of medicine. Judge William Q. Hayes of U.S. District Court for the Southern District of California sided with the J. Craig Venter Institute (JCVI) by dismissing the lawsuit brought against it by Human Longevity Inc. (HLI), the company Venter co-founded in 2014.


General Electric has filed paperwork for an IPO of its health-care unit, GE Healthcare, according to people familiar with the matter.

GE is working with JPMorgan Chase on an initial public offering that would likely come mid-2019, someone familiar with the plans told CNBC. Goldman Sachs, Bank of America, Citigroup and Morgan Stanley are also working with GE, according to Bloomberg News. The new public company would rank among the largest in the world.


It wouldn’t be a stretch to call 2018 the year RNA-based treatments, such as those applying RNA interference (RNAi) or small interfering RNA (siRNA), finally reached the proverbial tipping point predicted ever since Andrew Z. Fire and Craig C. Mello won the 2006 Nobel Prize in Physiology or Medicine for discovering RNAi.


Emergent BioSolutions Inc. (NYSE:EBS) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for its anthrax vaccine, BioThrax® (Anthrax Vaccine Adsorbed). BioThrax is indicated for active immunization for the prevention of disease caused by Bacillus anthracis, in individuals 18 through 65 years of age, whose occupation or other activities place them at risk of exposure, regardless of the route of exposure. BioThrax is administered in a three-dose primary schedule (0, 1 and 6 months) with boosters at three-year intervals recommended thereafter. BioThrax was approved under the Extraordinary Use New Drug Regulations, which provide a regulatory pathway for products for which collecting clinical information for its intended use in humans is logistically or ethically not possible.


Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today has announced that the Eversense® Continuous Glucose Monitoring (CGM) System has been awarded one of Popular Science’s 2018 “Best of What’s New” Awards in the Health category.